ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective January 17.
Pritesh Shah, Novocure’s Chief Commercial Officer, will transition to a new leadership role as Chief Growth Officer. In this role, Mr. Shah will have global responsibility for product and portfolio strategy, brand management, creating a global framework for new launches, market access and market intelligence. Mr. Shah will also be responsible for new indications in the United States.
Following a review of Novocure’s future needs, Ely Benaim, MD, Chief Medical Officer, will step down from his role and leave the company. dr Benaim will work with Novocure’s leadership team to ensure a smooth transition of responsibilities. The company wishes Dr. All the best for the future, Ben. Piet Hinoul, MD, Ph.D., currently Senior Vice President & Head of Global Medical Affairs, will assume the role of interim Head of Medical to ensure business continuity as the Company continues its external search for the next Chief Medical Officer . dr Hinoul will report to Mr Shah while Novocure completes its executive search.
Uri Weinberg, MD, Ph.D., currently Chief Science Officer, will transition to a new role as Chief Innovation Officer. In this role, Dr. Weinberg will be responsible for expanding the innovative potential of Tumor Treating Fields therapy. Moshe Giladi, Ph.D., currently Senior Vice President, Preclinical Research, will assume the role of Chief Science Officer at Novocure.
“We believe that the successful evaluation of LUNAR marks the beginning of a transformational phase for Novocure, with several key studies nearing completion and numerous future studies preparing for launch,” said Asaf Danziger, Chief Executive Officer of Novocure. “Our leadership needs will continue to evolve with our anticipated growth. We are committed to ensuring we have the optimal structure to support our people, the company and the thousands of patients we believe we will soon have the opportunity to serve in a multi-indication future to treat.”
Novocure is a global oncology company working to extend survival for some of the most aggressive types of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating tumor treatment areas in brain metastasis, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland, Novocure has a growing global footprint, with regional operations centers in Portsmouth, New Hampshire and Tokyo, and a research center in Haifa, Israel. For more information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.
In addition to statements of historical fact or current status, this press release may contain forward-looking statements. Forward-looking statements represent Novocure’s current expectations or projections of future events. These may include statements about expected scientific progress of its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers, and others Statements regarding matters that are not historical facts. You can identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” or other words and terms of similar meaning Meaning. Novocure’s performance and financial results may differ materially due to general financial, economic, environmental, regulatory and political conditions, as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties Novocure faces differ from those reflected in these forward-looking statements as set forth in its annual report on Form 10-K filed on February 24, 2022 and subsequent filings with the US Securities and Exchange Commission. Given these risks and uncertainties, some or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Additionally, Novocure does not intend to publicly update any forward-looking statements, except as required by law. Any forward-looking statements contained herein speak only as of the date of this release. The Private Securities Litigation Reform Act of 1995 permits this discussion.